Prostate‐specific antigen‐positive extramammary Paget's disease––association with prostate cancer

Hammer, Anne; Hager, Henrik; Steiniche, Torben

doi:10.1111/j.1600-0463.2008.00816.x

Cited by 13 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostatic adenocarcinoma is positive for p501S but negative for GATA3 whereas EMPD shows an opposite profile [28–30, 43, 53]. Prostatic adenocarcinoma can be rarely positive for GCDFP15 and primary EMPDs can show positive prostate specific antigen (PSA) staining in as many as 30% cases [43, 53]. Therefore, one cannot rely on PSA or GCDFP15 to distinguish primary EMPD from secondary PD caused by prostatic adenocarcinoma.…”

Section: Discussionmentioning

confidence: 99%

GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15

et al. 2017

View full text Add to dashboard Cite

BackgroundGATA-binding protein 3 (GATA3) has been identified as a sensitive marker for breast carcinoma but its sensitivity in primary genital extramammary Paget diseases (EMPDs) has not been well studied.MethodsHere we investigated immunohistochemical expression of GATA3 in 72 primary genital EMPDs (35 from female, 37 from male; 45 with intraepithelial disease only, 26 with both intraepithelial disease and invasive adenocarcinoma including 14 also metastasis, 1 with metastatic adenocarcinoma only for study). We also compared GATA3 to gross cystic disease fluid protein 15 (GCDFP15) for their sensitivity.ResultsPositive GATA3 staining was seen in all 71 (100%) intraepithelial diseases, 25/26 (96%; female 10/10, male 15/16) invasive adenocarcinomas and 14/15 (93%; female 3/3, male 11/12) metastatic adenocarcinomas, respectively. Positive GCDFP15 staining was seen in 46/71 (65%; female 28/34 or 82%, male 18/37 or 49%) intraepithelial diseases, 20/26 (77%; female 9/10, male 11/16) invasive adenocarcinomas, and 12/15 (80%; female 2/3, male 10/12) metastatic adenocarcinomas, respectively (GATA3 versus GCDFP15: p < 0.01 for both intraepithelial disease and invasive adenocarcinoma, p = 0.28 for metastatic adenocarcinoma). In positive-stained cases, GATA3 stained more tumor cells than GCDFP15 (79% versus 25% for intraepithelial disease, 71% vs 34% for invasive adenocarcinoma, 73% vs 50% for metastatic adenocarcinoma, p < 0.01 for all 3 components).ConclusionsOur findings indicate that GATA3 is a very sensitive marker for primary genital EMPDs and is more sensitive than GCDFP15.

show abstract

Section: Discussionmentioning

confidence: 99%

GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The first case of extramammary Paget's disease (EMPD) involving the male genitalia was reported by Crocker in 1889 6 . EMPD is an uncommon entity that may arise as a manifestation of an underlying adnexal apocrine carcinoma, 7–9 prostatic carcinoma, 10–12 rectal/anal carcinoma 13–15 or as a seemingly primary epidermal neoplasm without an associated carcinoma 16–19 …”

mentioning

confidence: 99%

Pigmented extramammary Paget's disease of the axilla mimicking melanoma: case report and review of the literature

Hilliard¹,

Huang

Andea³

2009

J Cutan Pathol

View full text Add to dashboard Cite

Pigmented Paget's disease is a rare variant that is often confused clinically and histologically with melanoma in situ. Herein, we describe a case of pigmented extramammary Paget's disease involving the axilla of a 79‐year‐old white male thought initially to represent malignant melanoma clinically and histologically. Review of the literature reveals that pigmented variant of Paget's disease, either mammary or extramammary, could be initially misdiagnosed as melanoma unless this entity is considered in the differential diagnosis, and additional confirmatory studies are performed.

show abstract

“…PSA positivity can be seen in cases of EMPD without associated adenocarcinoma of the prostate (11). The incidence of prostate cancer of EMPD patients is 10.4% (5/48) compared to 9.2% in the general population (4).…”

Section: Discussionmentioning

confidence: 99%

“…Until now, no clear correlation between prostate cancer and EMPD has been demonstrated. There are also reports that immunohistochemical investigations of the tumor specimens from the prostate revealed an immunoprofile, which was very different from that of the primary skin lesion, and no case of EMPD with PSA positivity seems to represent an extension of an underlying prostatic adenocarcinoma (11). It is known that prostate cancer can be found in at least 1 ⁄ 3 of men in their 80s (12).…”

Section: Discussionmentioning

confidence: 99%

Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase*

Shi

Yao

et al. 2010

APMIS

View full text Add to dashboard Cite

Shi G, Ye D-W, Yao X, Zhang S, Dai B, Zhang H, Shen Y, Zhu Y, Zhu Y, Xiao W, Ma C. Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase. APMIS 2010; 118: 777–81.The aim of this study was to determine the incidence of prostate cancer in patients with extramammary Paget’s disease (EMPD). All cases of EMPD diagnosed between 1992 and 2007 in Shanghai Cancer Hospital were collected and analyzed for the incidence of prostate cancer. The median follow-up was 78 months. In total, 38 cases of invasive and 10 cases of in situ EMPD had been registered. A second malignancy was found in 28.9% (11/38) of patients with invasive EMPD and in 30% (3/10) of patients with in situ EMPD. Patients had an increased risk of developing a second cancer compared with the general population (standardized incidence ratio: 1.7; 95% confidence interval 1.2–2.4). Sixteen patients had serum prostate-specific antigen (PSA) level above 4 ng/mL; five developed prostate cancer, three of them with PSA levels beyond 100 ng/mL. The incidence of prostate cancer is 10.4% in this patient group. Patients with EMPD were more likely to have prostate cancer than the general population. Although the prognosis of EMPD is fairly good, a thorough search for a second tumor is recommended.

show abstract

Prostate‐specific antigen‐positive extramammary Paget's disease––association with prostate cancer

Cited by 13 publications

References 21 publications

GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15

GATA3 is a sensitive marker for primary genital extramammary paget disease: an immunohistochemical study of 72 cases with comparison to gross cystic disease fluid protein 15

Pigmented extramammary Paget's disease of the axilla mimicking melanoma: case report and review of the literature

Extramammary Paget’s diseases in men from the Shanghai area: its association with PSA level increase*

Contact Info

Product

Resources

About